RxDoctor Payments Data

Kimford Meador, MD

Epilepsy · Stanford, CANPI 1528095296

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $37,110 of the $50,371 with a category attached, or 73.7%. 11 manufacturers reported payments, led by UCB SA at 31.1% of the total. Reporting peaked in 2019 at $14,337 and has fallen 56.0% since, to $6,307 in 2025. Among epilepsy clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$50,371in general payments, 2019–2025

Across 43 payments — averaging $1171.41 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • UCB SA$16K
  • Neuropace, Inc.$7K
  • Eisai Inc.$7K
  • Medtronic$6K
  • UCB, Inc.$5K
  • Livanova USA, Inc.$5K
  • plus $5K from 5 others
$384,464in research payments, 2019–2025

Across 21 payments — averaging $18,308 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eisai Inc.$381K
  • Otsuka Pharmaceutical Development & Commercialization, Inc.$3K

What the payments were for

  • Consulting fees$37,11074%
  • Speaking & faculty fees$11,00022%
  • Travel & lodging$1,3393%
  • Food & beverage$7872%
  • Education$1340%

General payments by program year

19
20
21
22
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$50,371 in reported general payments places this provider in the 90th percentile of 46 epilepsy providers in California.

See all epilepsy providers in California

Medicare billing

Part B allowed, 2024
$48,558
Medicare patients
164
Services billed
280

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FycompaPerampanel12$36,503
EpidiolexCannabidiol (Cbd)11$29,714
Rufinamide16$28,793
ZonisadeZonisamide12$20,687
Lacosamide136$14,485
Lamotrigine ErLamotrigine19$14,447
VimpatLacosamide11$14,326
NayzilamMidazolam13$9,658
Levetiracetam118$6,902
Clobazam40$3,610
Divalproex Sodium ErDivalproex Sodium40$3,047
Lamotrigine88$2,505
Divalproex Sodium26$2,085
Zonisamide25$1,285
Levetiracetam ErLevetiracetam12$1,140

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Eisai Inc.Fycompa$6,709$36,50312 claims
UCB, Inc.Vimpat, Nayzilam$5,390$23,98424 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 46 epilepsy providers in California.

Other epilepsy in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →